Clinical Trials for Mesothelioma Patients: Immunotoxin Therapy Outcome Measures
Read about the outcome measures for a current clinical trial being conducted to study the effects of Immunotoxin Therapy for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, the study is currently being conducted only in Zurich, Switzerland.
Primary Outcome Measures:• Maximum tolerated dose of SS1(dsFv)-PE38 immunotoxin [ Designated as safety issue: Yes ]
• Pharmacokinetics of SS1(dsFv)-PE38 immunotoxin [ Designated as safety issue: No ]
• Antitumor response [ Designated as safety issue: No ]
Secondary Outcome Measures:
• Measurement of antibody formation to drug and impact on pharmacokinetics [ Designated as safety issue: No ]
Recruitment Information:
Recruitment Status: Recruiting
Enrollment: 24
Estimated Start Date: June 2007
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health
Other helpful links:
Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney
Study outline for program to treat mesothelioma with Immunotoxin